|
Thursday,
September 13th
|
|
|
|
|
1:00pm - 1:05pm
|
Introduction and
ISGIO Presidential Inauguration
|
|
|
Christopher
G. Willett, MD
|
|
|
|
|
1:05pm - 1:10pm
|
Welcome From the
President
|
|
|
David
H. Ilson, MD, PhD
|
|
|
|
|
Session 1: Esophageal/Gastric Cancer
|
|
Chairpersons:
David H. Ilson, MD, PhD
|
|
|
|
|
1:10pm - 1:40pm
|
GE
Junction and Esophageal Cancer: Treatment of Locally Advanced Disease
|
|
|
Debate
on Preoperative Therapy
|
| |
|
|
|
Chemotherapy Alone
is Appropriate Preoperative Therapy
|
|
|
Faculty
TBD
|
|
|
|
|
|
Chemotherapy and
Radiation Therapy is Necessary Preoperative Therapy
|
|
|
David
H. Ilson, MD, PhD
|
|
|
|
|
1:40pm - 1:50pm
|
Q and A
|
|
|
|
|
1:50pm - 2:10pm
|
Gastric Cancer:
Postoperative Treatment of Locally Advanced Disease
|
| |
|
|
|
Chemotherapy and
Radiation Are Needed in Resected Gastric Cancer
|
|
|
Christopher
G. Willett, MD
|
|
|
|
|
|
Chemotherapy Alone
is Appropriate Adjuvant or Neoadjuvant Therapy for
Gastric Cancer
|
|
|
Faculty
TBD
|
|
|
|
|
2:10pm - 2:15pm
|
Q and A
|
|
|
|
|
2:15pm - 3:00pm
|
Case
Presentations/Panel Discussion
|
|
|
|
|
|
Case 1: Stage IIB,
Her2-Positive Gastric Cancer
|
|
|
What
is appropriate adjuvant therapy: chemotherapy alone, chemotherapy plus
radiotherapy, or either plus trastuzumab?
|
|
|
Al
B. Benson III, MD
|
|
|
|
|
|
Case 2: Advanced
Disease
|
|
|
What
is the status of current chemotherapy in advanced esophagogastric
cancer, and what new agents are advancing clinical trials?
|
|
|
Jaffer
A. Ajani, MD
|
|
|
|
|
|
Panel Discussion
|
|
|
Moderator:
David H. Ilson, MD, PhD
|
|
|
Panelists:
Jaffer A. Ajani, MD; Christopher G. Willett, MD; Al B. Benson, MD
|
| |
|
|
3:00pm - 3:20pm
|
Proffered Papers
|
|
|
|
|
3:20pm - 3:35pm
|
Break/Poster
Session
|
|
|
|
|
Session 2: Pancreatic Cancer
|
|
Chairpersons:
Michael A. Choti, MD; Eileen M. O’Reilly, MD
|
|
|
|
|
3:35pm - 3:55pm
|
Update
on Clinical Trials in Adjuvant Therapy for Pancreatic Adenocarcinoma
|
|
|
Faculty
TBD
|
|
|
|
|
3:55pm - 4:00pm
|
Q and A
|
|
|
|
|
4:00pm - 4:20pm
|
Multidisciplinary
Management of Locally Advanced and Borderline Disease
|
|
|
Jason
B. Fleming, MD
|
|
|
|
|
4:20pm – 4:25pm
|
Q and A
|
|
|
|
|
4:25pm - 5:25pm
|
Case
Presentation/Panel Discussion
|
|
|
|
| |
Case 1: Resectable Distal Pancreatic Cancer
|
| |
Andrew
M. Lowy, MD
|
| |
|
| |
Case 2: Locally
Advanced Pancreatic Cancer
|
| |
Joseph
M. Herman, MD, MSc
|
| |
|
| |
Case 3: Recurrent
Pancreatic Cancer
|
| |
Faculty
TBD
|
| |
|
| |
Panel
Discussion
|
| |
Moderators:
Michael Choti, MD; Eileen O’Reilly, MD
Panelists:
Jason B. Fleming, MD; Andrew M. Lowy, MD, FACS; Joseph M. Herman, MD, MSc;
|
| |
|
|
5:25pm - 5:45pm
|
Proffered Papers
|
| |
|
|
Friday,
September14th
|
|
|
Session 3: Advanced Colon
Cancer
|
|
Chairpersons:
Howard S. Hochster, MD; Wells Messersmith, MD, FACP
|
|
|
|
|
8:00am - 8:45am
|
Debate:
Biologics in First-Line Therapy
|
|
|
Bevacizumab- Axel F. Grothey, MD
|
|
|
EGFR inhibitors- Howard S. Hochster, MD
|
|
|
No Biologic- Faculty TBD
|
|
|
|
|
8:45am - 9:00am
|
Q and A
|
|
|
|
|
9:00am - 9:20am
|
Maintenance
Therapy with Biologics
|
|
|
Johanna
C. Bendell, MD
|
|
|
|
|
9:25am - 9:25am
|
Q and A
|
|
|
|
|
9:25am - 9:55am
|
Case
Presentations/Panel Discussion
|
|
|
Case 1: Rectal
Cancer with Resectable Liver Metastases
|
|
|
Faculty
TBD
|
|
|
|
|
|
Panel Discussion
|
|
|
Moderators:
Howard S. Hochster, MD; Wells Messersmith, MD, FACP
Panelists:
Axel F. Grothey, MD; Johanna C. Bendell,
MD
|
|
|
|
|
9:55am - 10:05am
|
Proffered Papers
|
|
|
|
|
10:05am - 10:20am
|
Break/Poster
Session
|
|
|
|
|
Session 4: Hot Topics in Gastrointestinal Oncology
|
|
Chairpersons:
Christopher G. Willett, MD
|
|
|
|
10:20am - 10:40am
|
Genomics
in GI Cancer
|
|
|
Adam
Bass, MD
|
|
|
|
|
10:40am - 10:45am
|
Q
and A
|
|
|
|
|
10:45am - 11:05am
|
Infection
in GI Cancer: Helicobacter. Pylori
|
|
|
Faculty
TBD
|
|
|
|
|
11:05am - 11:10am
|
Q
and A
|
|
|
|
|
11:10am - 11:30am
|
Screening
for Colorectal Cancer with Emphasis on Stool DNA
|
|
|
David A. Ahlquist,
MD
|
|
|
|
|
11:30am - 11:35am
|
Q
and A
|
|
|
|
|
11:35am - 11:55am
|
GI
Cooperative Groups
|
|
|
Daniel G. Haller, MD
|
|
|
|
|
11:55pm - 12:00pm
|
Q
and A
|
|
|
|
|
12:00pm – 2:00pm
|
CME Satellite Symposium and Lunch
|
|
|
|
|
2:00pm - 2:15pm
|
Break/Poster
Session
|
|
|
|
|
Session 5: Localized/Adjuvant Colorectal Cancer
|
|
Chairpersons:
Axel F. Grothey, MD
|
|
|
|
|
2:15pm - 2:35pm
|
Molecular
Markers, Molecular Signatures and Treatment Decision in Stage II Colon Cancer
|
|
|
Daniel
J. Sargent, PhD
|
|
|
|
|
2:35pm - 2:40pm
|
Q and A
|
|
|
|
|
2:40pm – 3:00pm
|
What is the Optimal Duration of Adjuvant Therapy
in Colon
Cancer?
|
|
|
Faculty
TBD
|
|
|
|
|
3:00pm – 3:05pm
|
Q and A
|
|
|
|
|
3:05pm - 3:25pm
|
Laparoscopic
Surgery of Rectal Cancer: Are We There Yet?
|
|
|
Faculty TBD
|
|
|
|
|
3:25pm - 3:30pm
|
Q and A
|
|
|
|
|
3:30pm - 4:15pm
|
Case
Presentations/Panel Discussion
|
|
|
|
|
|
Case 1: Elderly
Patient with Stage III Colon
Cancer
|
|
|
Joleen M. Hubbard, MD
|
|
|
|
|
|
Case 2: Radiation
Therapy in Rectal Cancer
|
|
|
Manisha Palta, MD
|
|
|
|
|
|
Panel Discussion
|
|
|
Moderators:
Axel F. Grothey, MD
Panelists:
Daniel J. Sargent, PhD; Joleen
M. Hubbard, MD; Manisha
Palta, MD
|
|
|
|
|
4:15pm - 4:25pm
|
Proffered Papers
|
|
|
|
|
Saturday,
September 15th
|
|
Session 6: Neuroendocrine Tumors (NET)
|
|
Chairpersons:
Jonathan R. Strosberg, MD; Christopher G. Willett,
MD
|
|
|
|
|
8:00am - 8:20am
|
Advances
in Treatment of Pancreatic Neuroendocrine Tumors
|
|
|
Jonathan
R. Strosberg, MD
|
|
|
|
|
8:20am - 8:25am
|
Q
and A
|
|
|
|
|
8:25am - 8:45am
|
Transarterial Embolic Therapy for
Liver-Predominant NETs: Bland vs. Chemoembolization vs. Radioembolization
|
|
|
David Liu, MD
|
|
|
|
|
8:45am - 8:50am
|
Q and A
|
|
|
|
|
8:50am - 9:10am
|
Updates
on Pathologic Classification and Grading of NETs
|
|
|
David S. Klimstra,
MD
|
|
|
|
|
9:10am - 9:15am
|
Q
and A
|
|
|
|
|
9:15am - 10:00am
|
Case
Presentations/Panel Discussion
|
|
|
|
|
|
Case 1: Small Bowel Carcinoid with Progressive Bilobar
Hepatic Metastases
|
|
|
Jonathan
R. Strosberg, MD
|
|
|
|
|
|
Case 2: Metastatic
Non-Functioning Pancreatic Neuroendocrine Tumor
|
|
|
George
A. Fisher, MD, PhD
|
|
|
|
|
|
Panel Discussion
|
|
|
Moderators:
Jonathan R. Strosberg, MD; Christopher G. Willett,
MD
Panelists:
Michael A. Choti, MD; David Liu, MD; George A.
Fisher, MD, PhD; David S. Klimstra, MD |
|
|
|
|
10:00am - 10:20am
|
Proffered Papers
|
|
|
|
|
10:20am - 10:35am
|
Break/Poster Session
|
| |
|
|
Session 7: Hepatobiliary Cancer
|
|
Chairperson:
Mary F. Mulcahy, MD
|
|
|
|
|
10:35am - 10:55am
|
Systemic
Therapy for Advanced HCC: Beyond Sorafenib
|
|
|
Rebecca
A. Miksad, MD
|
|
|
|
|
10:55am - 11:00am
|
Q and A
|
|
|
|
|
11:00am - 11:20am
|
Hepatocellular Carcinoma: Novel
Molecular Approaches for Diagnosis, Prognosis and Therapy
|
|
|
Faculty TBD
|
|
|
|
|
11:20am - 11:25am
|
Q
and A
|
|
|
|
|
11:25am - 11:45am
|
Update in Diagnostic and Therapeutic
Interventions for Biliary Duct Cancer
|
|
|
Sri Komanduri, MD
|
|
|
|
|
11:45am - 11:50am
|
Q
and A
|
|
|
|
|
11:50am - 12:35pm
|
Case Presentations/Panel Discussion
|
|
|
|
|
|
Case 1: Small HCC in Patient with Viral Hepatitis
|
|
|
Weijing Sun, MD
|
|
|
|
|
|
Case 2: Multifocal Intrahepatic
Cholangiocarcinoma (Confined to Lobe)
|
|
|
Faculty
TBD
|
|
|
|
|
|
Panel Discussion
|
|
|
Moderators:
Mary F. Mulcahy, MD
Panelists:
Rebecca A. Miksad, MD; Sri Komanduri,
MD, MS; Weijing Sun, MD
|
|
|
|
|
12:35pm - 12:45pm
|
Proffered Papers
|
|
|
|
|
12:45pm - 1:00pm
|
Summary
|
|
|
David H. Ilson,
MD, PhD
|
